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                                                  Synopsis 
Mechanistic Insights into Translation and Replication of Hepatitis C  
Virus RNA: Exploring Direct-Acting Antivirals 
Hepatitis C virus (HCV), a blood-borne pathogen, is a small enveloped RNA virus belonging 
to the Hepacivirus genus of the Flaviviridae family. HCV infection represents one of the 
major health concerns affecting approximately 170 million people globally. Patients with 
chronic HCV infection are at risk of developing hepatic fibrosis, cirrhosis and hepatocellular 
carcinoma. No protective anti-HCV vaccine is available yet. Until recently, standard therapy 
based on pegylated interferon plus ribavirin, was inadequate in treating all the patients as it 
results in a sustained virological response in only 40 to 50 percent of patients infected with 
the most common genotype (gt 1). Advances in understanding host-HCV interactions have 
helped developing newer anti-HCV agents such as telaprevir and boceprevir. However, 
treatment success is still limited due to different factors including genotype specificity, high 
cost, potential drug-drug interactions, substantial side effects etc. 
The positive-sense single-stranded RNA genome of HCV is approximately 9.6kb long which 
is flanked by highly structured and conserved 5’ and 3’ untranslated regions (UTRs) at both 
ends. Unlike cap-dependent translation of host cell mRNAs, HCV translation is mediated by 
an internal ribosomal entry site (IRES) present majorly within the 5’UTR. Several reports 
have demonstrated the interaction of different cellular proteins with HCV-5’UTR and/or 
3’UTR, which include human La protein, polypyrimidine tract binding protein (PTB), poly 
(rC)-binding protein 2 (PCBP2) etc. These interactions of trans-acting factors with the UTRs 
may be important for HCV translation and/or replication. Earlier study from our laboratory 
revealed the importance of interaction of human La protein, by its central RNA recognition 
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motif (RRM), with the HCV IRES around a tetranucleotide sequence GCAC near initiator 
AUG in influencing HCV translation. However, the role of this interaction, if any, in HCV 
RNA replication was not known. In the first part of the thesis, we characterized the 
interaction between human La protein and the GCAC to understand its role in HCV 
replication. We incorporated mutation, which altered the binding of La, in the GCAC motif in 
HCV monocistronic replicon and checked HCV RNA replication by reverse transcriptase 
polymerase chain reaction (RT-PCR). The mutation drastically inhibited HCV replication. 
Interestingly, overexpression of La could reverse the effect of this mutation and significantly 
enhanced HCV RNA levels. Using a bicistronic replicon, we observed that decrease in 
replication was independent of translation inhibition. Furthermore, mutation at the GCAC 
motif reduced the association between La and viral polymerase, NS5B as seen in co-
immunoprecipitation assays. Moreover, this mutation affected translation to replication 
switch regulated by the interplay between HCV-NS3 protease and human La protein. Our 
analyses of point mutations, based on RT-PCR and luciferase assays, revealed distinct roles 
of each nucleotide of the GCAC motif in HCV replication and translation. Finally, 5’-3’ 
crosslink assays revealed that specific interaction of the GCAC motif with human La protein 
is important for linking 5’ and 3’ends of HCV genome. Results clearly demonstrate the 
mechanism of regulation of HCV replication by interaction of cis-acting element GCAC 
within the HCV IRES with human La protein. 
HCV is highly species-specific. Under natural conditions, HCV infects only humans and 
chimpanzees. This restricted host-tropism has prevented the development of a small animal 
model to study HCV infection in vivo. Although several human-specific entry factors have 
been identified to be responsible for this species selectivity, full multiplication of the HCV in 
animals (other than humans and chimpanzees) is still not possible. In the second part of the 
thesis, we showed that a post-entry host factor –‘La protein’ may also contribute in 
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determining HCV host tropism. We aligned La protein sequences from different species and 
interestingly we found that HCV RNA interacting beta-turn sequence (KYKETDL) in central 
RRM (residues 112-184) is conserved only in human and chimpanzee. Earlier, it was shown 
from our laboratory that a heptameric peptide comprising of this sequence (derived from 
human La) could inhibit HCV translation by competing with La interaction with the IRES 
element. However, in the current study, another peptide corresponding to the mouse La 
sequence (KYKDTNL) was unable to inhibit HCV RNA translation. Similarly, wild-type 
mouse La (mLa) failed to stimulate HCV IRES function, but  addition of chimeric mouse La 
protein bearing human beta-turn sequence (mLahN7) significantly increased HCV IRES 
mediated translation in vitro. Also, exogenous supplementation of mLahN7 enhanced HCV 
translation in cell culture system. Moreover, quantitative as well as tagged RT-PCR analyses 
showed an enhanced HCV replication upon overexpression of mLahN7. The findings 
obtained in this part raise a possibility of creating HCV mouse model using human specific 
cellular entry factors and a humanized form of La protein. 
Hepatitis C has emerged as a major challenge to the medical community. Developing more 
potent and safe anti-HCV regimens is need of the hour. As described above, a linear 
hepatapeptide (KYKETDL) was synthesized and shown to reduce HCV translation. 
However, this linear peptide was stable only for a shorter time scale. Therefore, in the third 
part of the thesis, effect of a more stable cyclic form of this peptide has been described. NMR 
spectroscopy suggested that the beta turn conformation is preserved in cyclic peptide as well. 
Also, using in vitro bicistronic reporter assay, we demonstrated that cyclic peptide inhibits 
HCV translation in a dose dependent manner. In fact, due to its higher stability, cyclic peptide 
reduced HCV translation and replication more efficiently than the corresponding linear 
peptide at longer post-treatment time point. Additionally, we observed that cyclic peptide is 
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non-toxic in cell culture system. Our results suggest that cyclic peptide might emerge as a 
promising lead compound against hepatitis C.   
Due to availability of only partially effective liver protective drugs in modem medicine, 
complementary and alternative medicine approach, based on plant derived compounds, is 
also being utilised against HCV. Plant derived compounds have advantages of having high 
chemical diversity, drug-likeliness properties and ability of being metabolized by the body 
with little or no toxicity than synthetic ones. Different studies have shown that 
phytochemicals may exert anti-HCV activities by acting as direct-acting antivirals and play a 
potential therapeutic role in treating HCV infection. Also, from our laboratory, it was shown 
that methanolic extract of Phyllanthus amarus (P. amarus) plant inhibited HCV replication. 
The fourth part of the thesis describes the study on the anti-HCV properties of several 
bioactive components from P. amarus extract. Using a fluorimetric assay, we demonstrated 
that two principal components of this extract, phyllanthin and corilagin reduced the HCV 
NS3 protease activity significantly in vitro. We also observed a sharp reduction in HCV 
negative sense RNA levels in cell culture system. Structural knowledge-based molecular 
docking studies showed interactions of phyllanthin and corilagin with the amino acid residues 
of the catalytic triad of NS3 protease. Further, these compounds were found to be non-toxic 
in cell culture. Also, phyllanthin and corilagin displayed antioxidant properties by blocking 
HCV induced oxidative stress generated by reactive oxygen species suggesting their 
hepatoprotective nature. More importantly, our in vivo toxicity analyses and 
pharmacokinetics studies proved their safety, tolerability, metabolic stability, and systemic 
oral bioavailability and support their potential as novel anti-HCV therapeutic candidates. 
Altogether, the study deciphers mechanistic details of translation and replication of HCV 
RNA and demonstrates novel antiviral agents targeting these important viral processes. 
